Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
IRVINE, Calif., March 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq:PETX). Investors who purchased or otherwise acquired shares between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Aratana during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint states that throughout the Class Period, Aratana made false and/or misleading statements and/or failed to disclose: that the Company did not have manufacturing contracts in place sufficient to support manufacturing of its appetite stimulation drug ENTYCE at a commercial scale; ENTYCE was not likely to be commercially available until late 2017; the Company had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and that as a result of the above, Aratana’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, the Company disclosed that the Center for Veterinary Medicine requested more information about ENTYCE. Aratana told investors that it “now anticipates that ENTYCE … will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.”
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
